Evidence map›Paper›PMID 34943429›Full record

ArticleDiagnostics (Basel, Switzerland)2021

Digital Pathology Transformation in a Supraregional Germ Cell Tumour Network.

Richard Colling, Andrew Protheroe, Mark Sullivan, Ruth Macpherson, Mark Tuthill, Jacqueline Redgwell, Zoe Traill, Angus Molyneux, Elizabeth Johnson, Niveen Abdullah and 18 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diagnostics (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors at 5 institutions in 1 country.

Richard CollingNuffield Department of Surgical Sciences, University of Oxford, Oxford OX3 9DU, UK.ORCID 0000-0001-6344-9081
Andrew ProtheroeDepartment of Oncology, University of Oxford, Oxford OX3 9DU, UK.
Mark SullivanUrology Department, Oxford University Hospitals NHS Foundation Trust, Oxford OX3 9DU, UK.
Ruth MacphersonRadiology Department, Oxford University Hospitals NHS Foundation Trust, Oxford OX3 9DU, UK.
Mark TuthillOxford Cancer and Haematology Centre, Oxford University Hospitals NHS Foundation Trust, Oxford OX3 9DU, UK.
Jacqueline RedgwellUrology Department, Oxford University Hospitals NHS Foundation Trust, Oxford OX3 9DU, UK.
Zoe TraillRadiology Department, Oxford University Hospitals NHS Foundation Trust, Oxford OX3 9DU, UK.
Angus MolyneuxPathology Department, Milton Keynes University Hospital NHS Foundation Trust, Milton Keynes MK6 5DL, UK.
Elizabeth JohnsonPathology Department, Milton Keynes University Hospital NHS Foundation Trust, Milton Keynes MK6 5DL, UK.
Niveen AbdullahPathology Department, Milton Keynes University Hospital NHS Foundation Trust, Milton Keynes MK6 5DL, UK.
Andrea TaibiDepartment of Cellular Pathology, North Bristol NHS Trust, Bristol BS10 5NB, UK.
Nikki MercerDepartment of Cellular Pathology, Great Western Hospitals NHS Foundation Trust, Swindon SN3 6BB, UK.
Harry R HaynesDepartment of Cellular Pathology, Great Western Hospitals NHS Foundation Trust, Swindon SN3 6BB, UK.
Anthony SackvilleDepartment of Cellular Pathology, Oxford University Hospitals NHS Foundation Trust, Oxford OX3 9DU, UK.
Judith CraftDepartment of Cellular Pathology, Oxford University Hospitals NHS Foundation Trust, Oxford OX3 9DU, UK.
Joao ReisDepartment of Cellular Pathology, Oxford University Hospitals NHS Foundation Trust, Oxford OX3 9DU, UK.
Gabrielle ReesDepartment of Cellular Pathology, Oxford University Hospitals NHS Foundation Trust, Oxford OX3 9DU, UK.
Maria SoaresDepartment of Cellular Pathology, Oxford University Hospitals NHS Foundation Trust, Oxford OX3 9DU, UK.
Ian S D RobertsDepartment of Cellular Pathology, Oxford University Hospitals NHS Foundation Trust, Oxford OX3 9DU, UK.
Darrin SiiankoskiDepartment of Cellular Pathology, Oxford University Hospitals NHS Foundation Trust, Oxford OX3 9DU, UK.
Helen HemsworthDepartment of Cellular Pathology, Oxford University Hospitals NHS Foundation Trust, Oxford OX3 9DU, UK.
Derek RoskellDepartment of Cellular Pathology, Oxford University Hospitals NHS Foundation Trust, Oxford OX3 9DU, UK.
Sharon Roberts-GantDepartment of Cellular Pathology, Oxford University Hospitals NHS Foundation Trust, Oxford OX3 9DU, UK.
Kieron WhiteDepartment of Cellular Pathology, Oxford University Hospitals NHS Foundation Trust, Oxford OX3 9DU, UK.
Jens RittscherInstitute of Biomedical Engineering, University of Oxford, Oxford OX3 7DQ, UK.
Jim DaviesDepartment of Computer Science, University of Oxford, Oxford OX1 2JD, UK.
Lisa BrowningDepartment of Cellular Pathology, Oxford University Hospitals NHS Foundation Trust, Oxford OX3 9DU, UK.
Clare VerrillNuffield Department of Surgical Sciences, University of Oxford, Oxford OX3 9DU, UK.
Oxford University Hospitals NHS Trust · GBUniversity of Oxford · GBMilton Keynes Hospital · GBGreat Western Hospital · GBNorth Bristol NHS Trust · GB

Funding

NIHR Oxford Biomedical Research Centre n/aUK Research and Innovation 104689
6 · The paper itself

Abstract

backgroundIn this article we share our experience of creating a digital pathology (DP) supraregional germ cell tumour service, including full digitisation of the central laboratory.

methodsDP infrastructure (Philips) was deployed across our hospital network to allow full central digitisation with partial digitisation of two peripheral sites in the supraregional testis germ cell tumour network. We used a survey-based approach to capture the quantitative and qualitative experiences of the multidisciplinary teams involved.

resultsThe deployment enabled case sharing for the purposes of diagnostic reporting, second opinion, and supraregional review. DP was seen as a positive step forward for the departments involved, and for the wider germ cell tumour network, and was completed without significant issues. Whilst there were challenges, the transition to DP was regarded as worthwhile, and examples of benefits to patients are already recognised.

conclusionPathology networks, including highly specialised services, such as in this study, are ideally suited to be digitised. We highlight many of the benefits but also the challenges that must be overcome for such clinical transformation. Overall, from the survey, the change was seen as universally positive for our service and highlights the importance of engagement of the whole team to achieve success.

Indexed as

digitalgerm cellpathologytestis

Identifiers

PMID34943429
PMCPMC8700654
OpenAlexW3217412585

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.